Board summary
Key figures
28,144
Registered population
57.0% aged 18–64
23.5%
Aged 65+
ICB 20.0% · England 17.9%
3.1%
Ethnic minority (non-White)
1.0% Asian · England 9.6%
61.4%
In IMD quintile 1
ICB 30.6% · England 21.0%
~16,465
Core20 residents (est.)
Resident basis; registered basis ~17,281 · see page 3
5,593
Hypertension register
+5.00% in 3 yrs · England +5.60%
464
SMI register
37.7% of Wyre's
1,014
COPD register
Reviews -11.34% in 3 yrs
Forecast to 2030
6,334
Hypertension patients, 2030
+741 on today
64.3%
QRISK ≥20% on statins, 2030
-0.13pp over 3 yrs
5.5%
Cancer prevalence, 2030
England 4.5%
Three things the board should see
COPD review rate fell over three years.
COPD annual reviews fell 11.3% over 2023 to 2025 to 68.9% (England +2.8% to 76.4%), with The Mount View Practice at 61.0%.
24-month vaccine uptake trails 95.0% target.
In Q1 2025/26 (cohort 56), 24-month MMR1 is 83.9% (England 88.3%) and 6-in-1 is 85.7% (England 92.2%), both below the 95.0% target.
Hypertension target control above England, though falling.
Hypertension treated to target is 73.3% against 70.3% in England and the ICB, though it fell 4.5% over 2023 to 2025 (England +3.6%).
Population, age and ethnicity
Fleetwood PCN has 23.5% aged 65+, exceeding England and ICB but below Wyre
Fleetwood PCN registers 28,144 patients across three practices. Patients aged 65+ account for 23.5% (6,614 patients), below Wyre (27.1%) but above the ICB (20.0%) and England (17.9%). Patients aged 0-17 comprise 19.5% (5,480), and aged 18-64 make up 57.0% (16,050). On a Census resident base rather than registered patients, 96.9% identify as White (Wyre 97.5%, ICB 87.8%, England 81.1%), with a 3.1% ethnic minority share. Primary care list size is projected to grow 2.7% to 2030 under an unverified projection method.
Age profile
65+: ICB 20.0%, England 17.9%
Ethnicity
Older people · falls rows are Wyre local-authority (LA) data, not PCN
| Measure | Local | North West | England | Period |
|---|---|---|---|---|
| Falls admissions, 65+, per 100,000 (Wyre LA) | 1,506 | 2,071 | 1,958 | 2024/25 |
| Diabetes with frailty: HbA1c ≤75 mmol/mol (PCN) | 85.5% | 82.9% | 81.9% | 2024/25 |
| Diabetes without frailty: HbA1c ≤58 mmol/mol (PCN) | 56.9% | 56.6% | 57.4% | 2024/25 |
| Falls admissions, 65 to 79, per 100,000 (Wyre LA) | 814 | 1,021 | 955 | 2024/25 |
| Falls deaths, all ages, per 100,000 (Wyre LA) | 11.5 | 18.2 | 14.8 | 2022‑24 |
Deprivation and Core20
At 61.4%, Core20 deprivation markedly exceeds Wyre and England across all member practices
Fleetwood PCN's Core20 share is 61.4%, well above Wyre (15.0%), the ICB (30.6%) and England (21.0%), with an average IMD decile of 3.0 (England 5.5). Across practices, Core20 concentration spans 13.4 pp: The Mount View Practice has 67.6% (8,450 estimated patients), Fleetwood Surgery has 59.8% (3,659), and Broadway Medical Centre has 54.3% (5,172). Resident estimates identify 16,465 Core20 individuals, though practice registered estimates sum to 17,281. The distribution combines high practice share at The Mount View Practice with high registered patient volume at Broadway Medical Centre.
% of patients in IMD quintile 1, by practice
Dashed line: England 21.0% · right column: Core20 patients, registered basis
PLUS groups and inclusion health
PLUS groups and inclusion health
464
SMI register
1.62% recorded prevalence
157
Learning disability register
0.55% recorded prevalence
10
Care homes, 347 beds
In the PCN catchment
10.6%
Provide unpaid care
Wyre, Census 2021
The PCN registers 464 patients with severe mental illness (1.6% vs Wyre 1.1%, ICB 1.2%, England 1.0%) and 157 with learning disabilities (0.6% vs Wyre 0.5%, ICB 0.6%, England 0.6%). Catchment services include 10 care homes with 347 beds, although resident registration is unconfirmed.
Severe mental illness: physical health checks
SMI prevalence is 1.6% (England 1.0%). While 80.8% had a blood pressure check (England 83.4%), only 72.8% had a recorded BMI (England 82.1%), dropping to 65.0% at The Mount View Practice, showing uneven metabolic monitoring across practices.
Clinical focus: hypertension and lipids
Clinical focus: hypertension and lipids
5,593
Hypertension register
+5.00%
Register growth, 3 yrs
Wyre +7.69% · England +5.60%
−3.62pp
BP control, under 80
≤140/90 · −3.59pp aged 80+
+741
More patients by 2030
Forecast 6,334 (21.57%)
Hypertension case-finding and control
Fleetwood PCN records 5,593 patients on its hypertension register, a 19.6% prevalence trailing Wyre (21.7%) but exceeding the ICB (17.2%) and England (15.2%). Blood pressure control under 80 is 70.4% (Wyre 70.1%; England 67.8%), ranging from 64.4% at Broadway Medical Centre to 79.7% at Fleetwood Surgery. However, control under 80 fell 4.9% over 2023 to 2025 (England +3.2%), and hypertension treated to target fell 4.5% to 73.3% (England +3.6%). Falling three-year blood pressure control despite high recorded prevalence means the PCN should prioritise systematic recall and therapy reviews to reverse eroding control thresholds.
Lipids and statins
Patients with QRISK ≥ 20% on lipid-lowering therapy reach 64.6% (England 63.6%), but fell 0.2% over 2023 to 2025 (England +6.2%). Statin treatment for diabetes without cardiovascular disease trails England at 69.6% (England 73.2%), falling 6.1% (England +2.1%). Trailing statin uptake in diabetes requires prioritising recall of eligible diabetic patients for primary prevention.
| Measure | Items | Cost / item | ICB | England | Annual spend |
|---|---|---|---|---|---|
| Lipid-modifying, 2026 | 70,410 | £1.20 | £1.64 | £1.86 | £84,492 |
| Cardiovascular (all), 2025 | 106,995 | £3.40 | £3.38 | £3.33 | £363,783 |
For lipid-regulating drugs in 2026, the PCN prescribed 70,410 items at £1.20 per item (Wyre £1.45; ICB £1.64; England £1.86), spending £84,492 (£46,471 less than at England's unit cost), though unit cost does not indicate clinical efficiency. Lower unit costs than England mean the PCN can prioritise reviewing undertreated high-risk patients without excessive expenditure pressure.
Clinical focus: respiratory, cancer register and children
Clinical focus: respiratory, cancer register and children
Respiratory
−2.90%
Asthma reviews, PCN 3-yr % change
+4.44%
Asthma reviews, England 3-yr % change
−2.29%
Asthma prevalence, PCN 3-yr % change
COPD prevalence is 3.5% (1,014 patients; England 1.9%), but COPD annual reviews fell 11.3% over three years to 68.9% (England +2.8% 3-year change; England 76.4%), dropping to 61.0% at The Mount View Practice. Asthma prevalence is 8.0% (2,165 patients), and asthma reviews fell 2.9% over three years to 68.4% (England +4.4% 3-year change; England 65.7%). Prescribing of asthma management items for ages 5 to 19 is 2,658 per 1000 (England 1,488).
Cancer register and children's immunisation
Cancer prevalence is 4.5% (1,275 patients; England 3.8%). In childhood immunisations, 24-month uptake lags behind the 95.0% target: MMR dose 1 is 83.9% (below target by 11.1 pp; England 88.3%) and 6-in-1 complete primary course is 85.7% (below target by 9.3 pp; England 92.2%). By contrast, age-5 MMR2 coverage reaches 94.8% (England 82.8%).
Dashed line: 95% national coverage target · solid tick: England
Early cancer diagnosis
Early cancer diagnosis
52.4%
Lancashire and South Cumbria ICB, stage 1–2
55.3%
England, 2022
75%
National ambition by 2028
~2,010
Extra early-stage cases a year to reach the ambition
| Stage 1–2 share by cancer type, 2022 | Lancashire and South Cumbria ICB | England | No usable stage | Staged cancers |
|---|---|---|---|---|
| Breast | 86.0% | 85.4% | 6% | 1,561 |
| Prostate | 42.4% | 53.2% | 11% | 1,404 |
| Lung | 31.1% | 33.8% | 15% | 1,374 |
| Bowel | 44.2% | 47.0% | 13% | 1,198 |
| Skin cancer | 86.1% | 87.8% | 21% | 519 |
In 2022 across NHS Lancashire and South Cumbria ICB, 52.4% of staged cancers were diagnosed at stage 1 or 2, down 1.2 pp since 2013 and trailing England (55.3%), needing about 2,010 extra early-stage cases to reach 75.0%. In Fleetwood PCN, cervical screening coverage aged 25-49 is 63.7% (England 66.8%; Wyre 73.0%), with a -3.4% three-year change over 2023 to 2025 (England -1.0%). Breast screening coverage is 60.5% (England 69.9%; Wyre 73.4%), with a +21.0% change over 2023 to 2024 (England +8.4%). System stage data describes the ICB, not PCN performance. Lower PCN screening coverage may slow early case identification, indicating a need for systematic recall.
Cancer waits, diagnostics and community services
Cancer waits, diagnostics and community services
Cancer waits and diagnostics, Jul 2026 (provisional)
In July 2026, Blackpool Teaching Hospitals NHS Foundation Trust achieved 67.5% on the cancer 62-day standard, below the ICB (73.6%) and England (71.2%). For the 28-day faster diagnosis standard, the trust achieved 71.4% (ICB 78.4%; England 79.3%), while meeting the 31-day standard at 98.0% (ICB 93.6%; England 92.5%). Across all diagnostic tests, 26.5% of patients waited 6+ weeks at the trust (England sum of providers 23.1%). These acute figures reflect provider performance rather than PCN-specific cohorts. Provider diagnostic and treatment waits could extend patient pathways following cancer referrals from primary care.
| Pathways within standard (%) | Blackpool | of Morecambe Bay | Lancashire | Lancashire and South Cumbria ICB | England |
|---|---|---|---|---|---|
| 28-day faster diagnosis (75%) | 71.38 | 78.39 | 82.90 | 78.39 | 79.32 |
| 31-day treatment (96%) | 97.96 | 95.22 | 89.43 | 93.62 | 92.50 |
| 62-day referral to treatment (85%) | 67.48 | 72.35 | 75.04 | 73.62 | 71.16 |
| Diagnostic waits over 6 weeks (%) | Blackpool | of Morecambe Bay | Lancashire | England |
|---|---|---|---|---|
| MRI | 21.80 | 4.04 | 2.41 | 21.40 |
| CT | 16.49 | 13.76 | 14.97 | 9.92 |
| Echocardiography | 7.57 | 10.55 | 13.85 | 28.48 |
| Colonoscopy | 13.08 | 0.60 | 0.00 | 30.83 |
| Gastroscopy | 12.47 | 1.45 | 0.00 | 29.02 |
| All 15 DM01 tests | 26.54 | 10.44 | 26.65 | 23.14 |
| Community services activity | Lancashire residents | Lancashire and South Cumbria ICB |
|---|---|---|
| Care contacts | 126,445 | 193,720 |
| Referrals | 20,415 | 29,855 |
| Patients with a contact | 47,320 | 65,335 |
Community services (residents of Lancashire), Jun 2026 (provisional). In June 2026, provisional community services activity recorded 293,090 care activities for Lancashire residents, within 533,345 activities across NHS Lancashire and South Cumbria Integrated Care Board. Contacts with adults aged 65+ accounted for 56.9% of borough residents' contacts. These counts reflect submitting provider activity and are not unique PCN patients.
Practice variation and patient experience
Practice phone contact ease varies by 29.3 percentage points across the PCN
Across 2025/26, overall QOF achievement exceeds England (92.5%) at Fleetwood Surgery (95.9%), The Mount View Practice (95.2%), and Broadway Medical Centre (94.7%). Vaccination achievement shows a 29.1 pp spread, from 53.1% at Broadway Medical Centre to 82.2% at The Mount View Practice. Personalised care adjustment rates range from 7.2% at Fleetwood Surgery to 13.1% at The Mount View Practice.
GP Patient Survey by practice
| Practice | Responses | % in IMD Q1 | Phone easy | Request led to appt | Overall good |
|---|---|---|---|---|---|
| Mount View | 113 | 67.6 | 62.4% | 62.0% | 86.7% |
| Fleetwood Surgery | 103 | 59.8 | 84.7% | 56.6% | 76.8% |
| Broadway | 110 | 54.3 | 55.4% | 66.6% | 66.6% |
| England | — | ~21 | 56.9% | 71.6% | 76.7% |
Where the PCN lags
Across 25 tracked measures, 16 trail England's three-year change, led by COPD reviews
Across 25 tracked measures, 16 trail England's three-year change. The largest relative shortfalls against England include COPD reviews, which fell 11.3% to 68.9% (England +2.8%), diabetes statin treatment, which fell 6.1% to 69.6% (England +2.1%), and hypertension treated to target, which fell 4.5% to 73.3% (England +3.6%). Conversely, notable three-year gains include breast screening coverage rising +21.0% (England +8.4%), alongside severe mental illness health checks where alcohol recording rose +8.0 pp (England +5.4 pp) and BMI checks rose +7.1 pp (England +5.1 pp).
3-year change · PCN vs England
Bars show the direction and scale of relative change. Orange: PCN · Grey: England.
COPD reviews
Dementia register
Diabetes statin (no CVD)
Hypertension treated to target
BP control, under 80
Breast screening (53-70)
Alcohol record (psychosis)
BMI record (SMI)
What the data can't tell us: gaps and local assets
What the data can't tell us: gaps and local assets
| Local assets and voluntary sector | PCN | Wyre | Asset | PCN | Wyre |
|---|---|---|---|---|---|
| Care homes (catchment) | 10 (347 beds) | n/a | Schools (catchment) | 17 | n/a |
| Children's centres | 2 | 7 | Places of worship | 12 | 83 |
| Libraries | 1 | 6 | Food banks (VCS) | n/a | 1 |
| Day centres (VCS) | n/a | 3 | Carers support groups (VCS) | n/a | 2 |
| Primary schools (LA maintained) | 5 | 31 | Primary academies | 2 | 6 |
| Special schools | n/a | 1 |
0 = the source returned zero. n/a = not held at this level. No data = no value returned; this does not mean zero.
Options for the PCN
Options for the PCN
Each option in full
Option 1
COPD annual review recall recovery
COPD review coverage is 68.9% across a COPD register of 1,014 patients (3.5% prevalence vs England 1.9%), compared with England (76.4%), Wyre (75.1%) and the ICB (76.9%), with a three-year change of -11.3% over 2023 to 2025 (England +2.8%). Moderate effort to run.
Evidence base: the copd register is the cohort for spirometry-confirmed diagnosis, annual review and inhaler technique; register size and growth set the workload those interventions must cover.
Policy anchor: Core20PLUS5 adults: chronic respiratory disease (COPD vaccination and exacerbation reduction); Tobacco and Vapes Bill: smokefree generation.
Option 2
Hypertension case-finding and titration review
Hypertension prevalence is 19.6% (5,593 patients; England 15.2%; Wyre 21.7%), a modelled gap of -1,307 to +508 patients on 28,144 list size. Control to target is 73.3% but fell 4.5% over 2023 to 2025 (England +3.6%). Moderate effort to run.
Evidence base: the hypertension register is the cohort for case-finding, blood-pressure control and AF anticoagulation; its size and growth set the workload those interventions must cover, and a shortfall in control shows up later as emergency admission.
Policy anchor: Core20PLUS5 (hypertension case-finding and optimal management); NHS CVD ambitions to 2029 on detection, treatment to target and statins for high-risk patients (CVDPREVENT).
Option 3
Structured asthma annual review recall
Asthma review coverage is 68.4% across 2,165 register patients (8.0% prevalence; England 65.7%; Wyre 68.7%), leaving 684 (rounded: about 680) without a recorded review after a 2.9% three-year fall over 2023 to 2025 (England +4.4%). Low cost, quick to run.
Evidence base: the annual asthma review is the process gap between the register and outcomes.
Policy anchor: Core20PLUS5 chronic respiratory disease priority.
Provenance and audit trail
Provenance and audit trail
Figures are the profile's, drawn from Coplug indicator tables: census, deprivation and QOF measures, MHCLG, Rough sleeping snapshot in England: autumn 2025, OHID, Fingertips diabetes by frailty status: HbA1c control (93712, 93713) and OHID, Fingertips falls: emergency admissions, 65+ and 65 to 79 (22401, 22402), accidental-fall deaths (94002). Every recommended action and option is the profile's own; the evidence-base statements that support them — what each register is the cohort for, and the national policy it serves — are quoted from Coplug's indicator catalogue. No recommendation in this report is authored outside the profile and that catalogue. ICB- and provider-level data (page 8) describes the system the PCN sits in and is not read as PCN performance.
| Recommendation | Indicator(s) | Policy anchor | Data level |
|---|---|---|---|
| Older adult proactive care coordination (p2) | Aged 65+ | Neighbourhood health framework · NHS vaccination strategy | PCN |
| Targeted Core20 outreach and support (p3) | Core20 cohort (IMD quintile 1) | Core20PLUS5 · 10YHP equity test | PCN |
| SMI physical health checks (p4) | SMI register with a BMI recorded in the last 12 months | MHIS · From Harm to Hope | PCN |
| Hypertension recall and titration review (p5) | Last BP reading of patients (<80 yrs with hypertension) in the last 12 months is <= 140/90 mmHg (denominator incl. PCAs) | Core20PLUS5 CVD · CVDPREVENT 2029 | PCN |
| Early childhood immunisation catch-up (p6) | MMR dose 1 coverage at 24 months | 10YHP sickness to prevention · 95% target | PCN |
| Screening recall and uptake review (p7) | Women (25-49 yrs) with a record of cervical screening in the last 3.5 yrs (denominator incl. PCAs) | Fit for the Future: 10 Year Health Plan for England · Medium Term Planning Framework 2026 | PCN |
| Practice access and triage review (p9) | GPPS easy to contact the practice by phone | 10YHP, hospital to community | Practice |
| Option 1 · COPD annual review recall recovery (p12) | COPD register · COPD: QOF prevalence · COPD patients with a review in the last 12 months | Core20PLUS5 approach · Tobacco and Vapes Bill | PCN & Practice |
| Option 2 · Hypertension case-finding and titration review (p12) | Hypertension register · Hypertension: QOF prevalence · Registered population | Core20PLUS5 CVD · CVDPREVENT 2029 | PCN & Practice |
| Option 3 · Structured asthma annual review recall (p12) | Asthma register · Asthma: QOF prevalence · Patients with Asthma: review in the last 12 months (denominator incl. PCAs) | Core20PLUS5 respiratory | PCN |
Data sources
Data sources
Every figure in this profile comes from a dataset below, at the level and period stated. Nothing published above PCN level is read as PCN performance.
| Dataset | Level | Period | Used for |
|---|---|---|---|
| Coplug indicator tables: census, deprivation and QOF measures | PCN & Practice | 2023 to 2025, projected to 2030; 2023 to 2024 | Pages 1, 2, 3, 4, 5, 6, 7, 8, 10, 12 |
| MHCLG, Rough sleeping snapshot in England: autumn 2025 | Local authority | Autumn 2025 | Pages 2, 4 |
| OHID, Fingertips diabetes by frailty status: HbA1c control (93712, 93713) | PCN | 2024/25 | Pages 2, 4 |
| OHID, Fingertips falls: emergency admissions, 65+ and 65 to 79 (22401, 22402), accidental-fall deaths (94002) | Local authority | 2024/25; 2022-24 | Pages 2, 4 |
| ONS, Census 2021 TS039: provision of unpaid care (age-standardised) | Local authority | Census 2021 | Pages 2, 4 |
| QOF registers, prevalence and care processes (Coplug indicator tables) | Practice | 2023 to 2025, projected to 2030 | Pages 4, 5, 6, 7, 8, 10 |
| UKHSA, COVER supplementary GP data, childhood immunisation coverage, Q1 2025/26 | PCN & Practice | Q1 2025/26 | Pages 4, 6 |
| UKHSA, Seasonal influenza vaccine uptake in GP patients, 2025 to 2026 | ICB | 2025/26 season to 28 Feb 2026 | Pages 4, 6 |
| NHS England, Cancer Waiting Times: July 2026 monthly time series with revisions | ICB & Provider | Jul 2026 (provisional) | Pages 7, 8 |
| NHS England, Community Services Statistics (CSDS): June 2026 provisional experimental data | ICB & Local authority | Jun 2026 (provisional) | Pages 7, 8 |
| NHS England, Monthly Diagnostics Waiting Times and Activity (DM01): provider by test, July 2026 | Provider | Jul 2026 | Pages 7, 8 |
| National Disease Registration Service, Stage at diagnosis by cancer site in England, 2013 to 2022 | ICB | 2022 | Pages 7, 8 |
| NHS England / Ipsos, GP Patient Survey 2026: practice results (weighted) | Practice | Survey Jan-Apr 2026 | Page 9 |
| NHS England, Quality and Outcomes Framework 2025-26: achievement by practice and domain | Practice | 2025/26 | Page 9 |
| NHS England, Quality and Outcomes Framework 2025-26: personalised care adjustments by practice and domain | Practice | 2025/26 | Page 9 |
| Coplug indicator catalogue — definitions, cohorts, policy anchors | Reference | Current | Evidence-base lines, page 13 |
Methods, data-quality notes and limitations
Methods, data-quality notes and limitations
Methods
Estimated gaps apply benchmark prevalence to the registered population and subtract the recorded register. They size the task; they are not confirmed missed patients.
Percentage points are the difference between two rates; a relative change is that difference as a share of the starting rate. Register changes are relative, over three years.
Forecasts to 2030 extend each indicator's current trajectory with no change in case-finding or service model: a baseline to act against, not a prediction.
Core20 is the most deprived 20% nationally (IMD quintile 1). Practice shares are not additive to the PCN figure. Ethnic minority is 100% minus White. Local-authority averages are unweighted.
